NEW YORK (GenomeWeb) – Duke University and Tempus are teaming up on a brain cancer research initiative.
Under the terms of the agreement, Tempus will provide sequencing and analysis for glioblastoma patients in a clinical study being conducted at Duke, using an engineered poliovirus for treatment. The trial began in 2012 and was awarded breakthrough status by the US Food and Drug Administration last year. Glioblastoma is a highly aggressive tumor that grows and spread quickly, the partners said.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?